<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451788</url>
  </required_header>
  <id_info>
    <org_study_id>TurkuUH</org_study_id>
    <nct_id>NCT01451788</nct_id>
  </id_info>
  <brief_title>Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery</brief_title>
  <official_title>Effectiveness Of Gelatin Matrix With Human Derived Thrombin On Blood Loss, Surgical Time, Hospital Stay And Complications In Adolescents Undergoing Spine Surgery For Adolescent Idiopathic Scoliosis: A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Finnish Paediatric Orthopaedic Study Group will perform a prospective randomized,&#xD;
      multicenter, clinical trial comparing Gelatin matrix with human derived thrombin (Floseal,&#xD;
      Baxter) and without use of Floseal in adolescents undergoing posterior spinal deformity&#xD;
      surgery for AIS (adolescent idiopathic scoliosis between 45 and 90 degrees) in Turku, Tampare&#xD;
      and Helsinki Children's Hospitals. Sixty patients will be randomized into the intervention&#xD;
      group receiving Floseal (n=30) and control group not receiving Floseal (n=30). Each&#xD;
      University Hospital will treat 10 Floseal and 10 conventional treated scoliosis patients&#xD;
      (block randomization). Both treatment groups will be allowed to use conventional blood saving&#xD;
      methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Posterior spinal deformity surgery can be associated with major blood loss,&#xD;
      especially from cancellous bone or epidural venous plexus. Products such as Gelatin Matrix&#xD;
      with bovine derived thrombin (Floseal) can be used to prevent blood loss in adult patients&#xD;
      undergoing spine surgery.&#xD;
&#xD;
      Aim: To document and compare effectiveness of Gelatin matrix with human derived thrombin with&#xD;
      conventional blood loss control methods in adolescents undergoing posterior spinal deformity&#xD;
      surgery for adolescent idiopathic scoliosis (AIS), who do not need vertebral column&#xD;
      resection.&#xD;
&#xD;
      Methods: The Finnish Paediatric Orthopaedic Study Group will perform a prospective&#xD;
      randomized, multicenter, clinical trial comparing Gelatin matrix with human derived thrombin&#xD;
      (Floseal, Baxter) and without use of Floseal in adolescents undergoing posterior spinal&#xD;
      deformity surgery for AIS (adolescent idiopathic scoliosis between 45 and 90 degrees) in&#xD;
      Turku, Tampere and Helsinki Children's Hospitals. Sixty patients will be randomized into the&#xD;
      intervention group receiving Floseal (n=30) and control group not receiving Floseal (n=30).&#xD;
      Each University Hospital will treat 10 Floseal and 10 conventional treated scoliosis patients&#xD;
      (block randomization). Both treatment groups will be allowed to use conventional blood saving&#xD;
      methods.&#xD;
&#xD;
      Main outcome measures:&#xD;
&#xD;
      Blood loss during surgery (millilitres) Drain output during 24 hours (millilitres) Total&#xD;
      blood loss (Blood loss during surgery + drain output, millitres) Used blood products (Red&#xD;
      cell, frozen plasma, and thrombocyte units) Time of surgery Hospital stay Cost benefit&#xD;
      analysis (blood product use, surgical time, hospital stay) Complications related to use of&#xD;
      Floseal as a secondary outcome measure.&#xD;
&#xD;
      Primary Hypothesis and expected outcomes: Use of Floseal will reduce blood loss and surgical&#xD;
      time in patients undergoing spine surgery for adolescent idiopathic scoliosis (Level-I&#xD;
      evidence). Cost benefit analysis will most probably show that the use of Floseal is cost&#xD;
      effective. E.g. the value of one allogenic Red Blood Cell unit is 400â‚¬. If no red blood cell&#xD;
      units are needed instead of the usual three, the reduced blood product use alone will cover&#xD;
      the extra costs of Floseal use. In addition, if no allogenic blood infusions are needed, the&#xD;
      risk of infections will probably be significantly less. Reduced surgical time and shorter&#xD;
      hospital stay may also be cost reducing findings in patients receiving Floseal.&#xD;
&#xD;
      Safety Aspects: Gelatin Matrix with human derived thrombin (Floseal, Baxter Biosurgery) is&#xD;
      indicated for blood loss control in patients undergoing spine surgery when other methods are&#xD;
      less effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total perioperative blood loss</measure>
    <time_frame>Surgery time (up to 8 hours) + first postoperative 24 hours</time_frame>
    <description>Total blood loss during surgery + drain output, millilitres</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Used blood products</measure>
    <time_frame>Surgery time (up to 8 hours) + first 24 hours postoperatively</time_frame>
    <description>Red cell, frozen plasma, and thrombocyte units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss during surgery</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>Blood loss during primary surgery, in millilitres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of surgery</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>Time of surgery (hours, minutes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Adolescent Idiopathic Scoliosis</condition>
  <arm_group>
    <arm_group_label>Conventional group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Floseal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelatin matrix with human derived thrombin (Floseal, Baxter)</intervention_name>
    <description>Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.</description>
    <arm_group_label>Floseal</arm_group_label>
    <other_name>Floseal, Baxter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be included if between 10 and 20 years of age, no contraindication for&#xD;
             Floseal use, posterior scoliosis surgery using total pedicle screw technique for AIS&#xD;
             with normal blood coagulation and normal whole spine magnetic resonance images except&#xD;
             spinal deformity (AIS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for anteroposterior surgery&#xD;
&#xD;
          -  Need for vertebral column resection&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Abnormalities in blood coagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilkka J. Helenius, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Turku Children's Hospital, Turku University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Central Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Children's Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FI-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCT</keyword>
  <keyword>Gelatin matrix</keyword>
  <keyword>thrombin</keyword>
  <keyword>idiopathic scoliosis</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

